Vaccination | Jotup

Veterinary Vaccine Global Market Forecast Report: A $19.86 Billion Market by 2033, Registering 7.3% CAGR During 2023-2033

Retrieved on:

Monday, March 18, 2024

In 2022, the global veterinary vaccine market held a value of $9.44 billion.

Key Points:

In 2022, the global veterinary vaccine market held a value of $9.44 billion.
The veterinary vaccine market holds significant importance in the animal health industry, with profound impacts on both animal welfare and public health.
The veterinary hospitals and clinics segment accounted for the largest share of the global veterinary vaccine market (by distribution channel) in FY2022.
Technological Advancements in Veterinary Vaccine: Technological advancements in veterinary vaccine development present significant opportunities for the veterinary vaccine market.

Pending Governor's Action, West Virginia Bill Would Allow Vaccine Choice for Select Students, More Closely Align WV with 45 Other States

Retrieved on:

Thursday, March 14, 2024

Health, WVHF, Speech, Growth, Physician, Patient, Religion, Public, Delegate, Coercion, First, House, SHF, Vaccination, Constitutional right, Multimedia, Privacy, Senate, Legislation

CHARLESTON, W.Va., March 14, 2024 /PRNewswire-PRWeb/ -- A bill seeking to exempt virtual public school students in West Virginia from vaccine mandates and allowing private/parochial schools to set their own policies has successfully navigated both chambers and currently awaits the Governor's signature. HB 5105 as passed by the House of Delegates in a 70-29 vote, originally featured an amendment introducing a religious exemption for all public and private school students. This amendment was removed during the Senate Health Committee's deliberations and a simplified version of the bill secured Senate approval with a vote of 20 to 12 on Saturday, March 8.

Key Points:

West Virginia's HB 5105 does not provide a religious exemption but will more closely align WV with the majority of states.
Forty-five other states offer religious and/or philosophical exemptions to vaccine mandates and 44 states allow physicians to exempt children for medical reasons.
West Virginia sits at the bottom of all states in its vaccine exemption rate; only New York has a comparably low rate.
Despite having the most stringent vaccine laws in the nation, West Virginia health statistics for children are among the worst.

Calder Biosciences Inc. Publishes Next-Generation Vaccine Technology in Nature Communications

Retrieved on:

Thursday, March 14, 2024

Health, Infection, GSK, Ageing, 3D, MD, RSV, Protein engineering, Antibody, Licensure, Respiratory syncytial virus, Vaccination, CSO, Vaccine, Paper, Animal, Nature Communications

BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc ., a next-generation vaccine company, has been published in a Nature Communications article ( https://www.nature.com/articles/s41467-024-46295-8 ) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.

Key Points:

BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc ., a next-generation vaccine company, has been published in a Nature Communications article ( https://www.nature.com/articles/s41467-024-46295-8 ) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.
Application of the technology not only dramatically improves potency, but also improves shelf-life of the vaccine at refrigerated temperatures that will facilitate distribution and delivery.
In the Nature Communications manuscript, Calder demonstrates that a high dose of their RSV vaccine achieves responses in aged, immunosenescent animals equivalent to responses in the young animal control group.
Calder also plans to apply its technology more generally in protein engineering, imparting thermostability as needed to additional subunit vaccines, biologics, or other targets.

New Report Measures States' Emergency Preparedness and Recommends Policy Actions to Strengthen the Nation's Readiness

Retrieved on:

Thursday, March 14, 2024

WASHINGTON, March 14, 2024 /PRNewswire/ -- Ready or Not 2024: Protecting the Public's Health from Diseases, Disasters, and Bioterrorism, released today by Trust for America's Health, identifies key gaps in national and state preparedness to protect residents' health during emergencies and makes recommendations to improve the nation's emergency readiness.

Key Points:

Based on nine indicators, the report tiers states, and the District of Columbia, into three readiness levels: high, middle, and low.
Additional areas of responsibility for the public health system are enhancing vaccine access and monitoring municipal water systems safety.
Focusing on eliminating health disparities, advancing health equity, and stemming the rise in chronic diseases is essential for enhancing the nation's emergency preparedness."
The report's findings showed both areas of strength in the nation's health emergency preparedness and areas that need attention.

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

Retrieved on:

Tuesday, March 12, 2024

Control, Single-frequency network, Conference, ATTD, Disease, Risk, Weight loss, Blood, Diabetes, Doctor of Philosophy, MD, Type 2 diabetes, Vaccination, A1C, BMI, Prediabetes, Medical device

NEW YORK, March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy.

Key Points:

Dario's cardiometabolic solution integrates digital tools, connected devices and intelligent technologies to deliver a personalized and integrated experience to help drive better outcomes through effective behavior change.
Today, members can utilize the Dario solution with or without a GLP-1 medication and receive support tailored to their unique need.
The first study presented at ATTD analyzed the data of members engaged in Dario's cardiometabolic solution to manage pre-diabetes, a condition that requires weight loss and regulation of A1c.
A second Dario study presented at ATTD evaluated the effectiveness of Dario's digital health solution as a means to improve flu vaccine awareness and rates.

World Vaccine Congress Draws Leaders from Government, Science and Industry

Retrieved on:

Monday, March 11, 2024

Convention center, Bee, Washington Convention Center, Congress, Walter, Global health, Mayo Clinic, Food and Drug Administration, Cancer, International, Science Advisory Board, World Health Organization, Immunization, Vaccination, Bangladesh Technical Education Board, Vaccine, Food, Pharmaceutical industry

WASHINGTON, March 11, 2024 /PRNewswire/ -- The world's top experts and policymakers, including government leaders, renown researchers and company executives driving vaccine development, will gather to discuss the latest progress in vaccines — from efforts to inoculate bees to a discussion of pathogens that could cause the next pandemic — at the World Vaccine Congress April 1-4.

Key Points:

"We have assembled the world's foremost experts and policymakers in the field of vaccination for the 2024 World Vaccine Congress," said Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and a member of the Science Advisory Board.
"This event represents an unparalleled opportunity for collaboration and innovation and promises to drive meaningful progress in global health.
It is a unique and massive forum for discovery and access to leaders across the field."
In-depth sessions also cover vaccine supply and logistics, veterinary vaccines, emerging diseases, and vaccine delivery.

Whooping cough is surging in Australia. Why, and how can we protect ourselves?

Retrieved on:

Friday, April 5, 2024

Cases are highest in Queensland and New South Wales, with more than 1,000 recorded in each state.

Key Points:

Cases are highest in Queensland and New South Wales, with more than 1,000 recorded in each state.
The last time Queensland recorded more than 1,000 cases in three months was the first quarter of 2013.
So what is whooping cough, why are cases rising now, and how can you protect yourself?

It’s most dangerous for babies

The initial symptoms of whooping cough resemble other cold and flu-like symptoms.
However, as the disease progresses into the second week, the coughing fits become worse and more frequent.
After or between bouts of coughing, patients may gasp for air and produce the characteristic “whoop” noise.
Immunity from these vaccines wanes over time, so it’s also recommended adults receive a booster, particularly those who may come into frequent contact with babies.

Why are cases rising now?

Due to COVID measures such as border closures, social isolation and masks, the number of cases declined dramatically during 2020–23.
In Australia, cases have been particularly high during this outbreak in children aged 10–14.

A potential superbug

Most vaccines used in Australia and other developed countries stimulate your immune system to recognise and target three to five components of the bacteria.
These mutations make the bacteria look slightly different to the one used in the vaccine, helping it better hide from the immune system.

But in 2008, a new strain appeared in Australia that no longer produced pertactin, one of the components targeted by the vaccine.
This means your immune system, like a detective, has one less clue to recognise the bacteria.
Read more:
Low vaccination and immunity rates mean NZ faces a harsh whooping cough winter – what needs to happen

What next?

Greater tracking of whooping cough strains, like we do with COVID, is needed to inform future vaccine design and treatments.
Importantly, although the bacteria is evolving, current vaccines are still very effective at preventing serious disease and reducing transmission.

Laurence Don Wai Luu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Consumer participation in the credit market during the COVID-19 pandemic and beyond

Retrieved on:

Tuesday, April 2, 2024

Tax, BLS, Face, La Cava, Liquidity, Journal of Economic Perspectives, Special, MRO, Recovery, Next Generation, Child, Interview, Transport, Attanasio, Consumer behaviour, DFR, Research Papers in Economics, Post-Keynesian economics, Gross domestic product, .177 caliber, Great Moderation, European Commission, Vaccine, Employment, Loan, PDF, Hall, House, ECB, Unemployment, Risk, Shock, Education, Rutgers University Press, Quarterly Journal, Policy, Real estate economics, EU Council, Woman, HHS, World Health Organization, Section 4, Clutch (eggs), MIT Press, Omicron, De Nederlandsche Bank, Social science, Federal Reserve Bank, Modigliani, EDS, JEL, Christian Social Union (UK), Female, Section 3, COVID-19, The Journal of Finance, Journal, Classification, News, Journal of Monetary Economics, Oxford Economic Papers, Death, Insurance, Journal of Economics, FRB, FED, Credit, HFCS, Economy, Deficit reduction, Vaccination, Princeton University Press, Literature, CES, Application, University of Oxford, Paper, R.E, Quarterly Journal of Economics, Section 2, European Central Bank, Civil service commission, C23, COVID, Conference, European Council, Central bank, Lifting, HH, Political economy, Consumer confidence index, European Parliament, MIT, RRF, Monetary economics, Household, Perception, Section 5, Bank, Structure, Reproduction, Website, HICP, Aimé Dossche, Working paper, Housing, Cambridge, Massachusetts, Heart, Fabbri, American Economic Review, Partner, Data, Collection, Probability, Government, Real estate

We find that credit demand is highest when

Key Points:

We find that credit demand is highest when
the first lockdown ends and it drops when supportive monetary compensation schemes are implemented.
Credit is more likely to be
accepted under favourable borrowing conditions and after the approval of national recovery plans.
We also find
that demographic, economic factors, perceptions and expectations are associated with the demand for credit and
the credit grant.
First, it adds to a rapidly growing literature on household
borrowing behaviour during the COVID-19 pandemic; see, for example, Ho et al.
We provide evidence that credit applications and credit acceptances display a different pattern over
time.
Credit is more likely to be accepted under favourable borrowing conditions and after the
approval of national recovery plans.
In almost all countries
households are significantly less likely to apply and to get their credit approved than in Germany.
In line with literature, we show that
demographic and economic factors affect the probability for credit applications and credit approval.
In addition,
the paper shows that consumer perceptions and expectations matter when they decide to apply for credit.
Introduction
The participation of households in the credit market receives wide attention in the consumer finance literature
because consumer credit enters the monetary policy transmission mechanism through the so-called ?credit
channel?: changes in credit demand and supply have an effect on consumers' spending and investment, which in
turn affect economic growth.
We use microdata from the ECB?s Consumer Expectations Survey (hereinafter CES), a survey that
measures consumer expectations and behaviour in the euro area.
Its panel dimension allows for an assessment of
how consumer behaviour changes over time and how consumers respond to critical economic shocks.
This way we can gauge how credit applications and credit acceptances change under different, almost
opposite, borrowing conditions.
We also distinguish between the demand for long-term secured loans (mortgages) and for short-term
uncollateralized loans (consumer loans).
ECB Working Paper Series No 2922
3

We use probit models to estimate the probability of the consumer to apply for credit and the credit being granted.
The rate peaks in 2020Q3 which reflects the rebound in the demand for loans when the first lockdown ended.
In almost all countries households are significantly less likely
to apply and to get their credit approved than in Germany.
However,
when it comes to credit acceptance, we observe that the two groups of households are more similar.
Finally, we find some heterogeneity with respect to the type of credit, particularly between secured and unsecured
debt.
The demand for
consumer credit is insignificant for liquid households and decreases significantly for constrained households in
the last two quarters of our timespan.
The first consists of a recently growing literature which
explores consumer behaviour in the credit market during the COVID-19 pandemic, mostly in the United States.
Sandler and Ricks (2020) show that consumers did not use credit card debt for financial liquidity in the early stage
of the COVID-19 pandemic.
(2020) report that credit card applications and new mortgage loans
declined during the first months of the pandemic in regions with more unemployment insurance claims.
Lu and
Van der Klaauw (2021) show that there was a sharp drop in consumer credit demand, especially for credit cards.
(2022) document that there was a substantial decrease in the usage of credit cards and home equity lines
of credit by Canadian consumers.
Our paper is also consonant with studies on the association between financial and demographic factors and
consumers? participation in the credit market as well as on the demand for specific types of credit.
January 2020 ? October 2020 - The two main events are the outbreak of the COVID-19 pandemic and the
consequential lockdowns in the euro area.
4 If the
respondent has applied for more than one type of credit, she is asked to refer to the most recent credit application.
Between 2021Q3 and 2022Q3 the acceptance
rate stays above the average values, mirroring the easing of credit standards for consumer credit and other lending
to households during this period.
Second, we can investigate the presence of nonlinearities in how liquidity and the credit type interact in explaining credit applications.
(2023) ? who show that in the United States the local pandemic severity had a strong
negative effect on credit card spending early in the pandemic, which diminished over time.
First, we select mortgages and consumer credit as the two mostly reported categories for secured and
13

The full estimation results are reported in Table 3.
The right-hand side panel of Figure 6 shows that the demand for consumer credit is insignificant for both liquid
and illiquid households.
It also shows that
subjective perceptions of credit access, financial concerns and expectations on interest rates matter for the demand
for credit.
In Bertola, G., Disney
R., and Grant, C. (eds) The Economics of Consumer Credit, Cambridge MA, MIT Press.
Horvath, A., Kay, B. and Wix, C. (2023) The COVID-19 shock and consumer credit: Evidence from credit card
data.
Magri, S. (2007) Italian households? debt: The participation to the debt market and the size of the loan.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on:

Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points:

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on:

Wednesday, March 6, 2024

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points:

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
“Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.